A new paper has described the development of a self-directed intervention that harnesses digital technologies for psychedelic preparation.
A new study from the University of Chicago has investigated whether neural complexity is increased after low doses of LSD, and moderate to high doses of...
Lykos Therapeutics, formerly MAPS Public Benefit Corporation, has announced it has received FDA acceptance and priority review for a New Drug Application (NDA) concerning its MDMA-assisted...
The UK’s independent Parliamentary Office of Science and Technology (POST) has issued a rapid response on psychedelic-assisted therapy for anxiety disorders.
A new survey has revealed that over 79% of Canadians support psychedelic-assisted therapy for existential distress at the end of life.
A new study has shed light on the impact of psychedelics in patients taking SRIs, finding similar antidepressant effects as those not taking SRIs.
Marking a historic first for Europe, the European Union has funded research into psychedelic therapy as part of its Horizon Europe programme.
The European Medicines Agency (EMA) is set to hold a multi-stakeholder workshop on medical psychedelics in April 2024 to establish regulatory guidelines for the development and...
Beckley Psytech has confirmed it has received a strategic investment of USD$50 million from atai Life Sciences to accelerate the development of Beckley Psytech’s two clinical-stage,...
Doctors have raised a warning against so-called “trip killers” that are used to end challenging psychedelic experiences on compounds such as LSD or psilocybin.
Psychedelics Today recently surveyed students and graduates of its 12-month intensive professional psychedelic certification programme, Vital, publishing its findings in The Emerging Psychedelic Workforce report.
The first-ever psilocybin trial for treatment-resistant bipolar type II disorder has shown 80% of participants meeting remission criteria 12 weeks after treatment.